Literature DB >> 27081430

Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data.

Hidekatsu Yanai1, Yuji Hirowatari2, Kumie Ito3, Hideo Kurosawa4, Norio Tada5, Hiroshi Yoshida6.   

Abstract

Entities:  

Year:  2016        PMID： 27081430      PMCID： PMC4817584          DOI： 10.14740/jocmr2533w

Source DB:  PubMed          Journal:  J Clin Med Res        ISSN： 1918-3003


× No keyword cloud information.
  14 in total

1.  Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent.

Authors:  Yuji Hirowatari; Hiroshi Yoshida; Hideo Kurosawa; Ken-iti Doumitu; Norio Tada
Journal:  J Lipid Res       Date:  2003-05-01       Impact factor: 5.922

2.  Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man.

Authors:  E A Nikkilä; M R Taskinen; M Kekki
Journal:  Atherosclerosis       Date:  1978-04       Impact factor: 5.162

3.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

4.  Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol.

Authors:  Kumie Ito; Hiroshi Yoshida; Hidekatsu Yanai; Hideo Kurosawa; Ryo Sato; Daisuke Manita; Yuji Hirowatari; Norio Tada
Journal:  Int J Cardiol       Date:  2013-07-11       Impact factor: 4.164

5.  Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels.

Authors:  Hiroshi Yoshida; Yuji Hirowatari; Hideo Kurosawa; Daisuke Manita; Hidekatsu Yanai; Kumie Ito; Norio Tada
Journal:  Atherosclerosis       Date:  2012-03-30       Impact factor: 5.162

6.  Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats.

Authors:  C Sztalryd; F B Kraemer
Journal:  Metabolism       Date:  1995-11       Impact factor: 8.694

7.  Significance of hepatic triglyceride lipase activity in the regulation of serum high density lipoproteins in type II diabetes mellitus.

Authors:  S E Kasim; K Tseng; K L Jen; S Khilnani
Journal:  J Clin Endocrinol Metab       Date:  1987-07       Impact factor: 5.958

8.  Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism.

Authors:  E A Nikkilä; J K Huttunen; C Ehnholm
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

9.  Effects of diacylglycerol on glucose, lipid metabolism, and plasma serotonin levels in lean Japanese.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida; Yoshiharu Tomono; Yuji Hirowatari; Hideo Kurosawa; Akiyo Matsumoto; Norio Tada
Journal:  Obesity (Silver Spring)       Date:  2008-01       Impact factor: 5.002

Review 10.  Managing multiple cardiovascular risk factors: state of the science.

Authors:  Jon H Levine
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738
View more
  5 in total

Review 1.  Diabetic dyslipidemia: evaluation and mechanism.

Authors:  Hidekatsu Yanai; Yuji Hirowatari; Hiroshi Yoshida
Journal:  Glob Health Med       Date:  2019-10-31

2.  Which Nutritional Factors Are Good for HDL?

Authors:  Hidekatsu Yanai; Norio Tada
Journal:  J Clin Med Res       Date:  2018-10-30

3.  A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyama; Mariko Hakoshima
Journal:  Cardiol Res       Date:  2021-11-29

4.  Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyama; Mariko Hakoshima
Journal:  Biomedicines       Date:  2022-02-08

Review 5.  Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.

Authors:  Hidekatsu Yanai; Hiroki Adachi; Mariko Hakoshima; Hisayuki Katsuyama
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.